Key Takeaways:
- Bioprocessing Strength: Consumables grew double digits in Q3 driven by robust monoclonal antibody production, offsetting equipment weakness.
- Price Projection: The stock could reach $254 by December 2027.
- Potential Gains: This target implies a 8% total return from the current price of $235.
- Annual Return: Investors could see roughly 4% annual growth over the next 1.9 years.
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
Danaher (DHR) delivered a strong third quarter, beating revenue, earnings, and cash flow expectations. The company posted 3% core revenue growth with sales reaching $6.1 billion, while adjusted earnings per share jumped 10% to $1.89.
But the headline numbers only scratch the surface.
With bioprocessing consumables growing in the double digits, free cash flow conversion hitting 146%, and $2 billion deployed for share buybacks, including up to 35 million additional shares in Q3 alone, Danaher is demonstrating the earnings power of its portfolio even at modest growth rates.
The company generated $3.5 billion in free cash flow over the first nine months.
Despite strong execution and a clear path to margin expansion in 2026, DHR stock trades at $235, offering upside for investors who understand the company’s bioprocessing dominance and productivity-driven margin story.
See analysts’ full growth forecasts and estimates for DHR stock (It’s free) >>>
What the Model Says for Danaher Stock
We analyzed Danaher through the lens of CEO Rainer Blair’s execution strategy: leveraging the Danaher Business System to mitigate ongoing geopolitical and policy-related pressures and to drive productivity while investing in innovation across biotechnology, life sciences, and diagnostics.
The company is navigating cautious equipment spending in bioprocessing while maintaining strength in consumables tied to commercialized therapies. Management expects to deliver over 100 basis points of margin expansion in 2026 through operational leverage and $250 million in net cost savings.
Using a forecast of 4.4% annual revenue growth and 29.5% operating margins, our model projects the stock will reach $254 in 1.9 years. This assumes a 26.1x price-to-earnings multiple—flat from Danaher’s current P/E of 28.8x.
As the company absorbs $175 million in cost actions during 2025 and positions for accelerating growth in 2026, maintaining the current multiple is reasonable. The real value comes from the momentum in bioprocessing consumables and the operating leverage kicking in next year.
Our Valuation Assumptions
Estimate a company’s fair value instantly (Free with TIKR) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for DHR stock:
1. Revenue Growth: 4.4%
Danaher’s growth reflects a balanced outlook across its three segments with upside potential.
Bioprocessing Momentum: The company expects high single-digit core growth in bioprocessing for 2026, consistent with 2025 performance. Consumables remain strong, driven by robust global production of monoclonal antibodies, which represent 75% of Cytiva’s bioprocessing exposure.
FDA approvals remain elevated, with over two-thirds of the world’s top 100 drugs projected to be biologics by 2030.
Equipment Recovery Ahead: Management assumes flat equipment growth for planning purposes, but CEO Blair noted increasing confidence among pharma customers. Tariff clarity and workable most-favored-nation pricing agreements are removing investment decision overhangs. Early discussions about brownfield expansions to reshore manufacturing capacity could drive upside.
Diagnostics Acceleration: Growth should improve as the business moves past China policy headwinds. Beckman Coulter delivered its fifth consecutive quarter of mid-single-digit growth outside China, driven by the DxI 9000 analyzer. Cepheid’s installed base expansion continues, with respiratory revenue expected at $1.7 billion—consistent with 2025’s endemic rate.
Life Sciences Stability: Management expects modest improvement but assumes growth remains below historical levels, given ongoing academic and government funding pressures. Clinical and applied markets remain solid, while pharma R&D spending shows modest recovery.
2. Operating margins: 29.5%
Danaher operates with strong margins that are set to expand meaningfully in 2026.
Current Performance: Q3 adjusted operating margin reached 27.9%, up 40 basis points year-over-year. Higher volume leverage and disciplined cost management more than offset productivity investments.
Productivity Initiatives: The company is investing $175 million in cost actions during 2025, including $150 million in Q4 alone. These initiatives will generate total savings of $250 million in 2026, or roughly $0.30 of EPS tailwind.
Operating Leverage: Management expects 35% to 40% fall-through on revenue growth plus the benefit of cost actions, driving over 100 basis points of margin expansion in 2026. This translates to high single-digit EPS growth even at the low end of the revenue guidance range.
3. Exit P/E Multiple: 26.1x
The market currently values Danaher at 28.8x earnings. We assume modest compression to 26.1x for our exit multiple.
Below Historical Average: Danaher’s P/E has averaged 26.1x over the past year and 26.5x over 10 years. The current elevated multiple reflects strong free cash flow generation and the company’s track record. Some compression accounts for the transition year dynamics and cautious equipment spending environment.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Life sciences tools companies face varying end-market conditions and execution risks. Here’s how Danaher stock might perform through December 2029:
- Low Case: If revenue growth comes in at 5.2% and net income margins reach 23%, the stock offers a 3.1% annual return with a $266 target.
- Mid Case: With 5.7% growth and 25% margins (our base assumptions), we expect an 8.7% annual return and a $327 target.
- High Case: If equipment spending recovers and Danaher maintains 26% margins while growing at 6.3%, returns could hit 13.9% annually with a $392 target.
See what analysts think about DHR stock right now (Free with TIKR) >>>
The range reflects different scenarios for bioprocessing equipment recovery and end market improvement.
In the low case, equipment spending remains depressed longer, or China headwinds persist.
In the high case, reshoring investments accelerate equipment orders, academic funding improves, and the $250 million in cost savings drives stronger margin expansion than currently modeled.
How Much Upside Does Danaher Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
